NasdaqCM - Nasdaq Real Time Price
USD
Inovio Pharmaceuticals, Inc. (INO)
0.6024
-0.1694
(-21.95%)
At close: 4:00:01 PM EDT
1.9900
+1.3876
(+230.35%)
After hours: 7:41:35 PM EDT
Trade INO on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for INO
What's happening with INO?
Powered by Yahoo ScoutINOVIO received FDA accelerated approval for VOCERYQ, formerly known as INO-3107, for adults with recurrent respiratory papillomatosis. The approval creates a commercial launch opportunity, while requiring confirmatory studies and placing INOVIO in competition with Precigen’s established therapy.
Powered by Yahoo Scout
- Previous Close
0.7718 - Open
0.8637 - Bid 0.5900 x 100
- Ask 0.6985 x 100
- Day's Range
0.5961 - 0.8637 - 52 Week Range
0.5600 - 2.7200 - Volume
47,607,708 - Avg. Volume
4,195,378 - Market Cap (intraday)
62.287M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9000 - Earnings Date (est.) Nov 10, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
3.17 - Motley Fool Rating Bearish
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
INO
65.38%
S&P 500 (^GSPC)
10.73%
1-Year Return
INO
74.47%
S&P 500 (^GSPC)
11.11%
3-Year Return
INO
86.43%
S&P 500 (^GSPC)
81.91%
5-Year Return
INO
99.30%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/29/2026
-
Market Cap
79.80M
-
Enterprise Value
51.13M
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (current)
--
-
Price/Sales (ttm)
--
-
Price/Book (mrq)
14.54
-
Enterprise Value/Revenue
1.02k
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-84.23%
-
Return on Equity (ttm)
-409.87%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-67.43M
-
Diluted EPS (ttm)
-0.9000
Balance Sheet and Cash Flow
-
Total Cash (mrq)
36.67M
-
Total Debt/Equity (mrq)
183.07%
-
Levered Free Cash Flow (ttm)
-33.86M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
